Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Bavarian Nordic A/S (BV3A.F)

Compare

7.25

-0.20

(-2.68%)

As of 9:59:02 AM GMT+1. Market Open.

EC approves Bavarian Nordic’s chikungunya vaccine marketing

The announcement comes after US FDA approval in February 2025.

Pharmaceutical Technology 20 hours ago

BAVA.CO
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The virus-like particle (VLP) single-dose vaccine is

GlobeNewswire 3 days ago

BVNKF

BVNRY
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries. COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income (LMIC) countries. Initially, the companies have entered into a contract manufacturing agreement to

GlobeNewswire 7 days ago

BVNKF

BVNRY
Undiscovered Gems And 2 Other Promising Small Caps With Strong Potential

As global markets continue to navigate a landscape marked by rising inflation and cautious monetary policy adjustments, small-cap stocks have been trailing behind their large-cap counterparts, with the Russell 2000 Index underperforming the S&P 500. However, these conditions can often present unique opportunities for investors seeking potential growth in lesser-known companies that may thrive despite broader economic uncertainties. In this environment, identifying promising small caps...

Simply Wall St. 12 days ago

BVNKF

BVNRY
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Pharmaceutical Technology 15 days ago

BAVA.CO

VLA.PA
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also secured a strong foundation for 2025.Financial guidance for 2025 in line with the Company’s 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025. The preliminary revenue in 2024

GlobeNewswire 28 days ago

BVNKF

BVNRY
EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Pharmaceutical Technology last month

BAVA.CO

GLDAF
Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure and meeting the long-term obligations relating to the Company’s share-based incentive programs for the Board of Di

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in the first half of 2025, pending final marketing authorization. COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marke

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, with synergies from a number of recent and near-term expected events as described in the December 11 announcement. Bavarian Nordic will hold the shares

GlobeNewswire last month

BVNKF

BVNRY
Bavarian Nordic signs mpox vax deal with Serum Institute of India

The partnership aims to facilitate the vaccine's supply for the Indian market.

Pharmaceutical Technology 2 months ago

BAVA.CO
Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

Tech transfer of MVA-BN® will help increase global mpox vaccine manufacturing capacity and further expand the equitable access to vulnerable populations.Serum Institute of India obtains license to MVA-BN for the Indian market. COPENHAGEN, Denmark, December 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today a license and manufacturing agreement for its MVA-BN® mpox vaccine with Serum Institute of India Pvt. Ltd. (“SII”). Under the agreement, the companies will undertake a technology trans

GlobeNewswire 2 months ago

BVNKF

BVNRY
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NamePaul Chaplin2.Reason for the notification a)Position/status President and Chief Executive Officer of Bavarian Nordic A/S b

GlobeNewswire 2 months ago

BVNKF

BVNRY
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a new long-term incentive program for Executive Management and selected employees in the Bavarian Nordic Group. Members of the Executive Management are granted a mix of performance restricted stock units (Performance RSUs) and warrants, both subject to the successful achievement of relevant Key Performance Indicators (KPI’s). Employees participating in the

GlobeNewswire 2 months ago

BVNKF

BVNRY
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

COPENHAGEN, Denmark, December 11, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decision should be viewed in the context of improved visibility around the Company’s Travel Health business, driven by a number of completed and near-term expected events, including: A better-than-expected performance of the Travel Health business, as demonstrated by the recent guidance upgrade.The near-

GlobeNewswire 2 months ago

BVNKF

BVNRY
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 218,750 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. A total of 21,875 new shares were subscribed for in cash at DKK 146.60 per share of nominally DKK 10. The total proceeds to Bavarian Nordic A/S from the capital

GlobeNewswire 3 months ago

BVNKF

BVNRY
Bavarian Nordic AS (BVNKF) Q3 2024 Earnings Call Highlights: Strong Travel Health Growth and ...

Bavarian Nordic AS (BVNKF) reports robust travel health business growth and strategic advancements in vaccine launches amid logistical challenges.

GuruFocus.com 3 months ago

BAVA.CO
Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

Revenue for the mpox vaccine is down compared to last year however its travel vaccine business grew by 21%.

Pharmaceutical Technology 3 months ago

BAVA.CO
US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic

COPENHAGEN (Reuters) -Vaccine maker Bavarian Nordic expects the incoming Trump administration to boost biodefence funding despite the nomination of Robert F. Kennedy Jr., a vaccine sceptic, as health secretary, the company's CEO said on Friday. Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump selected Kennedy, who has previously spread misinformation on vaccines, to lead the top health agency. "Vaccine scepticism was part of Trump's first administration," Bavarian Nordic CEO Paul Chaplin told Reuters in an interview.

Reuters 3 months ago

BAVA.CO

Performance Overview

Return	BV3A.F	OMX Copenhagen 25 Index
YTD	-13.17%	+2.17%
1-Year	+10.69%	-5.73%
3-Year	-26.02%	+7.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bavarian Nordic A/S (BV3A.F)

EC approves Bavarian Nordic’s chikungunya vaccine marketing

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

Undiscovered Gems And 2 Other Promising Small Caps With Strong Potential

Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

EMA recommends Bavarian Nordic’s chikungunya vaccine for adults and teenagers

Bavarian Nordic – Completion of Share Buy-Back Program

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

Bavarian Nordic signs mpox vax deal with Serum Institute of India

Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Bavarian Nordic AS (BVNKF) Q3 2024 Earnings Call Highlights: Strong Travel Health Growth and ...

Bavarian Nordic shares sink by 12% after mpox sales slump in Q3

US expected to increase biodefence spending under Trump, says vaccine maker Bavarian Nordic

Performance Overview